Press coverage about Dipexium Pharmaceuticals (NASDAQ:PLXP) has trended positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Dipexium Pharmaceuticals earned a daily sentiment score of 0.28 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.3795613757772 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

PLXP has been the subject of several analyst reports. Zacks Investment Research raised Dipexium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. Redburn Partners upgraded Dipexium Pharmaceuticals to an “outperform” rating in a report on Tuesday, August 1st. Finally, UBS AG upgraded Dipexium Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a report on Monday, July 31st.

Shares of Dipexium Pharmaceuticals (NASDAQ PLXP) traded down $0.10 during midday trading on Tuesday, hitting $6.50. The stock had a trading volume of 1,009 shares, compared to its average volume of 23,488. Dipexium Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $22.00.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/07/favorable-media-coverage-somewhat-unlikely-to-impact-dipexium-pharmaceuticals-plxp-share-price.html.

Dipexium Pharmaceuticals Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Insider Buying and Selling by Quarter for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Receive News & Stock Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.